Clinical Study to Evaluate Safety and Effectiveness of Noble Lift® Lifting Threads
Launched by GCS CO., LTD · Jun 6, 2024
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the safety and effectiveness of two types of lifting threads, called Noble Lift® PDO sutures, used for cosmetic treatments. The study will compare how well these threads work for lifting different parts of the face, such as the upper face (like the eyebrows) and the mid to lower face. Researchers will assess how well the treatments improve appearance over a year, using patient feedback, photographs, and specific scales to measure changes.
To participate in this trial, you should be between 18.5 to 30 BMI, have dense skin that isn’t too thin, and need a lifting treatment for your upper or mid/lower face. However, certain conditions might disqualify you, such as being pregnant, having severe health issues, or recent facial procedures. If you join, you can expect to have the threads placed in a specific area and will be monitored for both safety and how much you like the results over the next year. This study is not yet recruiting participants, so there’s still time to consider if you meet the criteria and are interested in taking part.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • BMI comprised between 18.5 and 30
- • No ongoing or planned diet.
- • Group 1: requiring an aesthetic treatment of upper face with resorbable threads.
- • Group 2: Subject requiring an aesthetic treatment of mid-face and lower-face with resorbable threads
- • Subject with dense and not too thin skin.
- Exclusion Criteria:
- • Pregnant or nursing woman or planning a pregnancy during the study;
- • Suffering from a severe or progressive disease or any other pathology that may interfere with the evaluation of the study result and/or subject safety, especially cardiac disorder, non-controlled high blood pressure, diabetes, panic disorders, depression, active auto-immune disease, cold, high fever,...
- • Suffering from malnutrition.
- • Acute inflammatory process or infection, or history of chronic or recurrent infection or inflammation with the potential to interfere with the study results or increase the risk of adverse events.
- • Wound healing disorder or with a disorder that may impact wound healing such as connective tissue or immunosuppressive disorder.
- • History of precancerous lesions/skin malignancies.
- • Active skin disease within 6 months of study entry.
- • Scars, rosacea, herpes, acne, blotches or other pathology in the face, at the investigator appreciation.
- • Predisposed to keloidosis or hypertrophic scarring.
- • Known history of hyper- or hypo-pigmentation in the face.
- • Known history of multiple allergies, allergic/anaphylactic reactions including allergy/ hypersensitivity to lidocaine, anaesthetics of the amide type, the used antiseptic components, the used antibiotic cream components.
- • Known bleeding disorder or is receiving medication that will likely increase the risk of bleeding during treatment.
- • Extensive skin laxity, thin skin and/or severe malar fat sagging.
- • Foreign body sensitivity or known or suspected allergies to implant or instrument materials in particular plastic/biomaterial.
- • Any medication which may interfere, at the interpretation of the investigator, with the study objectives in term of efficacy and safety/tolerance.
- • Dental care in the past 2 weeks or who planned to receive dental care in the 2 months after the treatment.
- • Anticoagulant (such as aspirin, warfarin, blood circulation enhancer and clotbuster) during the week before the injection session .
- • Chemotherapy agents, immunosuppressive medications or systemic corticosteroids in the past 3 months and during the study.
- • Lifting of the face in the past 12 months or other surgery of the face in the past 6 months.
- • Resorbable fillers within the past 12 months, other resorbable threads within the past 12 months, neurotoxin in the past 5 months or plans to receive such treatments during the study.
- • Permanent filler on the face.
- • Subcutaneous permanent retaining structure on the face (meshing, permanent threads, gold strand etc.).
- • Intensive exposure to sunlight or UV-rays within the previous month and/or foreseen during the study.
About Gcs Co., Ltd
GCS Co., Ltd. is a pioneering clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a focus on delivering high-quality clinical solutions, GCS Co., Ltd. leverages cutting-edge technology and a robust network of experienced professionals to facilitate the efficient conduct of clinical trials across various therapeutic areas. Committed to regulatory compliance and patient safety, the company aims to accelerate the development of novel therapeutics, ensuring that breakthroughs in medicine reach the market effectively and responsibly. Through strategic partnerships and a patient-centered approach, GCS Co., Ltd. strives to enhance global health outcomes and contribute to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aix En Provence, , France
Cannes, , France
Lyon, , France
Paris, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported